Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT00109785
PET Scans in Patients With Locally Advanced Breast Cancer
Overview
RATIONALE: Imaging procedures such as PET scans may improve the ability to monitor the effectiveness of chemotherapy for locally advanced breast cancer. PURPOSE: This clinical trial is studying how well PET scans work in patients with locally advanced breast cancer who will undergo chemotherapy.
Sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Contacts
Teresa Ann Gilewski, MD (STUDY_CHAIR)
ClinicalTrials.gov
NCT00109785Drug / Compound
iododeoxyuridine
Isotope(s):
IODINE-124
Radioisotope: I-124
Theranostic Role: Imaging
T1/2 (Half-Life): 4.2 Days
Decay Mode: Electron Capture 74.4% and Positron Emission 25.6%
Energy: 2.138 MeV
Decay Daughters: Tellurium-124
Target(s):
- S-Phase replication
Ligand Class: Small Molecules
FDG
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- Glucose Transport
Ligand Class: Small Molecules
Eligibility
Inclusion
- 18 and overSex:
- Fertile patients must use effective contraceptionBiologic therapy
- Karnofsky 80-100%Hematopoietic:
- Hormone receptor status:
- Stage T3 T4, N2 or N3 disease
- Histologically confirmed locally advanced breast carcinoma
- Male or femaleMenopausal status:
Exclusion
- Not specifiedRenal:
- Not specifiedRadiotherapy
- Not specifiedChemotherapy
- Not specifiedOther:
- Not specifiedPerformance status:
- Not specifiedHepatic:
- Not specifiedEndocrine therapy
- Not pregnant
- Not specifiedSurgery
- Not specified
Share your feedback
Help us improve your experience